Ann: Remestemcel-L for COPD Published in Respiratory Research, page-3

Key findings from the analysis were:
• The greater the degree of inflammation, as measured by elevated CRP levels, the greater the signal of efficacy of remestemcel-L treatment in improving moderate to severe lung disease
• Significant improvements were observed in each of the pre-specified endpoints of forced expiratory volume, and forced vital capacity, with maximal effects seen at four months (both p <0.01)
• Significant increases were seen in six-minute walk test which is a major independent predictor of mortality in COPD2
• In patients with the highest level of CRP (>4mg/L), those who received remestemcel-L were able to walk 55 meters further than placebo-treated patients in the six-minute walk test at four months (p=0.004)